Endometrial mullerian adenosarcoma after toremifene treatment in breast cancer patients: A case report

Ye Won Chung, Hyo Sook Bae, Song I. Han, Jae Yoon Song, In Sun Kim, Seong Jae Kang

    Research output: Contribution to journalArticlepeer-review

    3 Citations (Scopus)

    Abstract

    Toremifene is an anti-estrogen which has been shown to be effective in the treatment of breast cancer, and is thought to be a less uterotrophic agent than tamoxifen. The risk assessment concerning endometrial cancer has been inconclusive because of its rare use up to the mid-1990s. We report a case of an adenosarcoma, which is a very rare type of uterine malignancy, after toremifene treatment for 5 years in a breast cancer patient. After 1 year of toremifene use, the patient had a benign Mullerian adenofibroma. After an additional 4 years of toremifene treatment, the endometrial polypoid lesion was transformed into a Mullerian adenosarcoma. Although toremifene is a promising anti-estrogenic agent in the treatment of breast cancer patients, clinicians should not neglect the possibility of a uterine malignancy.

    Original languageEnglish
    Pages (from-to)269-272
    Number of pages4
    JournalJournal of gynecologic oncology
    Volume21
    Issue number4
    DOIs
    Publication statusPublished - 2010 Dec

    Keywords

    • Breast cancer
    • Mullerian adenofibroma
    • Mullerian adenosarcoma
    • Tamoxifen
    • Toremifene

    ASJC Scopus subject areas

    • Oncology
    • Obstetrics and Gynaecology

    Fingerprint

    Dive into the research topics of 'Endometrial mullerian adenosarcoma after toremifene treatment in breast cancer patients: A case report'. Together they form a unique fingerprint.

    Cite this